Antagonist - PDFSEARCH.IO - Document Search Engine

Antagonist
Results: 956

#	Item
1	3273 Pan-Selectin Antagonist, GMI-1070 Decreases Venous Thrombosis in a Mouse Model Program: Hemostasis and Thrombosis Session: Vascular Wall Biology, Endothelial Progenitor Cells and Platelet Adhesion Tuesday, December Add to Reading List Source URL: glycomimetics.com Language: English - Date: 2012-10-05 11:31:04
2	#4503 A Small Molecule Glycomimetic Antagonist of E-selectin (GMIPrevents Pancreatic Tumor Metastasis and Offers Improved Efficacy of Chemotherapy Maria M. Steele1, BS, Prakash Radhakrishnan1, PhD, John L. Magnani Add to Reading List Source URL: glycomimetics.com Language: English - Date: 2014-04-10 23:45:38
3	E-selectin Antagonist GMI-1271 Shows a Favorable Safety, PK and Bleeding Profile in Phase I Studies of Healthy Volunteers of Medicine/Division of Hematology Oncology, University of Michigan, Ann Arbor, MI;2Section of Vas Add to Reading List Source URL: glycomimetics.com Language: English - Date: 2016-12-12 15:21:52
4	GMI-1271, a Novel E-Selectin Antagonist, Combined with Induction Chemotherapy in Elderly Patients with Untreated AML Daniel J. DeAngelo1, Brian A. Jonas2, Dale L. Bixby3, Pamela S. Becker4, Michael E. O’Dwyer5, Anjali Add to Reading List Source URL: glycomimetics.com Language: English* - Date: 2017-06-01 12:20:20
5	ADMINISTRATION OF THE DUAL E-SELECTIN/CXCR4 ANTAGONIST, GMI-1359, RESULTS IN A UNIQUE PROFILE OF TUMOR MOBILIZATION FROM THE BONE MARROW AND FACILITATION OF CHEMOTHERAPY IN A MURINE MODEL OF FLT3 ITD AML Abstract # 2826 Add to Reading List Source URL: glycomimetics.com Language: English - Date: 2016-12-12 15:21:24
6	The Dual E-selectin/CXCR4 Antagonist GMI-1359 Exerts Anti-leukemia Efficacy Against FLT3-ITDmutated Acute Myeloid Leukemia in A Patient-derived Xenograft Murine Model Mouse-1 Mouse-2 Add to Reading List Source URL: glycomimetics.com Language: English - Date: 2016-12-12 15:22:04
7 $A Phase I/II Study of GMI-1271, a Novel E-selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Previously Untreated Elderly Patients with Acute Myeloid Leukemia; Results to Date Dan$	A Phase I/II Study of GMI-1271, a Novel E-selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Previously Untreated Elderly Patients with Acute Myeloid Leukemia; Results to Date Dan Add to Reading List Source URL: glycomimetics.com Language: English - Date: 2016-12-05 13:18:26
8 $GMI-1271, a Potent E-Selectin Antagonist, in Combination with Chemotherapy in Relapsed/Refractory AML: A Novel, Well-Tolerated Regimen with a High Remission Rate Daniel J. DeAngelo*1, Brian A. Jonas2, Jane L. Liesveld3,$	GMI-1271, a Potent E-Selectin Antagonist, in Combination with Chemotherapy in Relapsed/Refractory AML: A Novel, Well-Tolerated Regimen with a High Remission Rate Daniel J. DeAngelo1, Brian A. Jonas2, Jane L. Liesveld3, Add to Reading List Source URL: glycomimetics.com Language: English* - Date: 2017-06-26 08:58:58
9	PRODUCT MONOGRAPH COZAAR® losartan potassium tablets 25, 50 and 100 mg Angiotensin II Receptor Antagonist Add to Reading List Source URL: www.merck.ca Language: English - Date: 2017-12-07 02:16:49
10	Cell, Vol. 92, 253–263, January 23, 1998, Copyright 1998 by Cell Press sprouty Encodes a Novel Antagonist of FGF Signaling that Patterns Apical Branching of the Drosophila Airways Nir Hacohen,* Susanne Kramer,† D Add to Reading List Source URL: cmgm.stanford.edu Language: English - Date: 2012-12-19 14:57:09